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Background: Free circulating microRNA (miRNA) in serummay be valuable biomarkers for disease diagnosis and
prognosis. miR-21, the archetypal oncogenic miRNA, has been proposed as a biomarker for colorectal cancer and
its benign precursor, adenomatous polyps. However, it is now becoming clear that circulating miRNA proﬁles
may be sensitive to lifestyle and environmental inﬂuences. Dietary components involved in one-carbon metab-
olism are particularly well placed to modulate miRNA expression through an inﬂuence on DNA methylation
pathways.
Methods:We investigated the role of methyl group donors (folate, B12, cysteine, homocysteine), polymorphisms
of the enzymes of one-carbon metabolism, and serum miR-21 expression in a primary case–control cohort
(colonoscopy conﬁrmed adenomatous colon polyps vs controls; n=253) and a secondary cross-sectional cohort
(over 65s; n = 649). The relationships between these parameters and serum miR-21 levels were assessed,
stratiﬁed by gender.
Conclusions: Serum miR-21 expression was related to occurrence of adenomatous polyps in females, but not
males. Folate levels and MTHFR-C677T genotype was associated with miR-21 expression in both genders.
Additionally, DHFR-19 del and MSR-A66G were associated with miR-21 expression in females and males,
respectively. Stimulation with excess folate increased expression of miR-21 in colon cancer cell lines.
General signiﬁcance: This study demonstrates that serum miR-21 expression correlates with folate status and
related genetic status. This may have consequences for the proposed use of miR-21 as a colorectal cancer
biomarker.
Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
MicroRNAs (miRNAs) are an abundant class of short, non-coding
RNA involved in post-transcriptional regulation of gene expression. It
has been estimated that miRNAs have a post-transcriptional regulatory
inﬂuence on themajority of humanmRNAs, and are thought to regulate
almost all cellular processes [1]. Unique signatures have been identiﬁed
in a range of disease tissues [2] including circulating miRNA in plasma
and serum [3]. Circulating miRNA are promising objective, non-
invasive and easily accessible biomarkers for disease diagnosis and
prognosis. They are remarkably stable, and can be detected with high
levels of speciﬁcity and sensitivity. Therefore, signiﬁcant potential existstal cancer.
nd Life Sciences, University of
Australia.
tt).
r B.V. This is an open access article uto use miRNA as practical biomarkers for detecting or staging a wide
range of diseases [4]. However, additional research is needed to unravel
the complex relationships between miRNA proﬁles and pathophysio-
logical conditions before this application can be fully realized.
miR-21 is the archetypal example of an oncogenic miRNA, and miR-
21 expression in serumor plasma has been suggested as a biomarker for
the diagnosis and prognosis in a number of cancers [5–9]. In the case of
colorectal cancer (CRC), increasing levels of circulating miR-21 have
been shown relative to healthy controls [5,10–12]. Furthermore,
serummiR-21 levels have been shown to increasewith disease progres-
sion, from healthy tissue to adenomatous polyps (AP; the benign pre-
cursor to CRC) to CRC, and between TNM stages of CRC [5,10].
Toiyama et al. have also demonstrated falling miR-21 levels in post-
surgical patients [10]. Although the sources of miR-21 in circulation
cannot be deﬁned, CRC cell lines have been shown to secrete miR-21,
and increased expression in serum correlates with increased expression
of miR-21 in CRC tissue [10].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. SerummiR-21 expression in adenomatous polyp cases versus controls inA) females
(n = 144) and B) males (n = 109). REU= relative expression units.
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are also known tomodulatemiRNA proﬁles [13–20]. miR-21 in particu-
lar has been shown to be modulated in the liver of rodents fed methyl-
donor deﬁcient [21–23] and high fat/high fructose diets [24]. High fat
diets have also been shown tomodulatemiR-21 levels in adipose tissues
in high fat induced obesity [25]. Additionally, dietary compounds such
as curcumin [26] and fatty acids [27,28] have been shown to modulate
miR-21 expression. While it is not yet clear how diet modulates levels
of circulating miR-21, diet is known to contribute to the modiﬁable
determinant of risk for CRC [29].
Given the role of aberrant DNA methylation proﬁles in cancer, the
potential of methyl-donor diets tomodulatemiR-21 levels is particular-
ly interesting, especially since methyl-donor nutrients are the major
source of methyl-groups in one-carbon metabolism cycles, and
therefore inﬂuence the availability of methyl-groups for use in biologi-
cal processes, including DNA methylation [30–32]. Methyl-donor
availability may inﬂuence miR-21 expression directly, through methyl-
ation of miRNA genetic loci, or indirectly via modulation of other epige-
neticmarks or genetic signalling pathways. It is recognized thatmethyl-
donor diet can inﬂuence methylation status, and therefore cancer risk
[33]. Folate, amajor contributor to themethyl-donor diet, has a complex
and non-linear relationship with cancer risk, with both high and low
folate potentially increasing risk [30,34].
Importantly, one-carbon metabolism is regulated by multiple
enzymes and co-factors. Therefore, polymorphisms in the genes that
code for these enzymes and co-factor levels can inﬂuence the outcomes
of this metabolic locus and potentially inﬂuence gene and miRNA
expression levels. Therefore, it seems prudent to examine the relation-
ship between levels of methyl-donors, co-factors, and polymorphismsTable 1
Selected characteristics of the primary cohort, cases vs. controls, stratiﬁed by sex.
Female
Case n = 26 Control n = 118 p case/cnt
Age (years)a 65.5 ± 1.7 59.3 ± 1.1 0.004
Age range 46–82 18–82
Smoking history
Currentb 9 (6.3) 27 (18.8)
Exb 6 (4.2) 37 (25.7)
Neverb 11 (7.6) 54 (37.5) 0.42⁎
MiR-21 (REU) 1.85 ± 0.70 0.07 ± 0.27 0.02
Red blood cell folate (μmol L−1) 1.29 ± 0.12 0.93 ± 0.04 0.009
Serum B12 (nmol L−1) 0.29 ± 0.02 0.28 ± 0.01 0.80
Cysteine (mmol L−1) 0.26 ± 0.01 0.26 ± 0.04 0.98
Homocysteine (μmol L−1) 12.41 ± 0.79 12.01 ± 0.40 0.65
a Mean ± SEM.
b Count (%total).
⁎ p-Value χ2.of one-carbon metabolism related enzymes, and levels of miR-21 in
circulation.
2. Methods
2.1. Subjects and sample collection
The primary cohort consisted of patients undergoing routine screen-
ing for colonic pathology at a gastroenterology clinic (n = 263 Gosford
Hospital, NSW, Australia). 253 participants (57% male) who gave blood
samples from which DNA and miRNA were successfully isolated, and
received a deﬁnitive diagnosis as to the presence or absence of AP
were included in this analysis. Participants were aged 18–89 (female
mean 60.4 ± 1.0 years, male mean 64.4 ± 1.2 years).
The secondary cohort was taken from a large cross-sectional cohort
of 1095 elderly participants, aged 65 years ormore, living on the Central
Coast of NSW, Australia. 649 participants (44.2% male), aged 65–
95 years (females 78.0 ± 0.4 years, males 77.5 ± 0.4 years) who gave
blood for analysis were included. Although colonoscopy was not per-
formed in this cohort, it is an appropriate secondary cohort, as age is a
known risk factor for development of AP and CRC, with the incidence
rate more than 50 times higher in the 60–79 age group compared to
individuals under 40 years of age [35]. Therefore, elderly patients
would be an important target population for the use of miR-21 as a
potential biomarker of CRC.
For both cohorts, bloodwas collected in heparin lined tubes (Greiner
Bio-one, Frickenhausen, Germany) and plasma isolated by centrifuga-
tion. Informed consent was obtained prior to participation under the
University of Newcastle Human Research Ethics Committee approval
numbers H-429-0407 and H-2008-0431.
2.2. Blood biochemistry
Folate and serum B12 were measured by chemiluminescent assay
[36,37]. Plasma homocysteine was measured by a single enzyme
homocysteine assay [31,38]. Serum cysteine levels were measured by
HPLC [36].
2.3. Genotyping
Eight variants in six genes involved in one-carbon metabolism
[DHFR-19 del (rs70991108), TS-2R3R (rs34743033), SHMT-C1420T
(rs1979277), MTHFR-C677T (rs1801133), MTHFR-A1298C (rs1801131),
MTHFR-G1793A (rs2274976), MS-A2756G (rs1805087), MSR A66G
(rs10380)], were examined using PCR, restriction enzyme digestions
and gel electrophoresis [31].Male Female vs male
rl Case n = 30 Control n = 79 p case/cntrl p case p cntrl
67.0 ± 2.1 63.4 ± 1.5 0.16 0.58 0.03
44–89 28–88
8 (7.3) 18 (16.5)
9 (8.3) 42 (38.5)
13 (11.9) 19 (17.4) 0.07⁎ 0.76⁎ 0.003⁎
−0.07 ± 0.40 0.50 ± 0.33 0.26 0.02 0.31
0.89 ± 0.07 1.1 ± 0.05 0.06 0.006 0.08
0.27 ± 0.02 0.27 ± 13.11 0.96 0.60 0.53
0.27 ± 0.08 0.27 ± 0.05 0.65 0.27 0.73
13.78 ± 1.21 13.62 ± 0.52 0.90 0.35 0.02
Table 2
Selected characteristics of the secondary cohort, stratiﬁed by sex.
Female n = 362 Male n = 287 p
Age (years)a 60.4 ± 0.96 64.4 ± 1.21 0.35
Age range 18–84 28–89
Smoking history
Currentb 10 (0.02) 11 (0.02)
Exb 122 (0.19) 180 (0.28)
Neverb 230 (0.35) 96 (0.15) b0.0001⁎
MiR-21 (REU) −0.42± 0.08 −0.09± 0.09 0.0065
Red blood cell folate (μmol L−1) 1.29± 0.02 1.23± 0.02 0.07
Serum B12 (nmol L−1) 0.24± 0.006 0.22± 0.007 0.05
Homocysteine (μmol L−1) 10.07± 0.28 11.34± 0.42 0.01
a Mean ± SEM.
b Count (%total).
⁎ p-Value χ2.
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miRNAs were isolated from plasma using Trizol LS and Glycoblue
[39,40]. Three synthetic Caenorhabditis elegans miRNA (cel-238, -54,
-38) were added to plasma samples as exogenous spike-in controls to
normalize data, as no appropriate endogenous house-keeping gene
has been identiﬁed in plasma [40,41]. cDNAwas synthesized using uni-
versal primers and qPCR primer design was conducted as per the rules
described by Balcells et al. [42]. Primer sequences used for miR-21
were (f) 5′- GCAGTAGCTTATCAGACTGAT -3′, (r) 5′- GGTCCAGTTTTTTT
TTTTTTTTCAAC -3′ [42]. Datawas analysed using qbase plus (Biogazelle,
Technologiepark, Belgium) [43]. Data was expressed as log transformed
relative expression units (REU). For reaction volumes and conditions
see Supplementary methods.Fig. 2.The relationship between serummiR-21 and erythrocyte folate inA) females (r2=0.248,
the primary cohort and C) females (r2 = 0.140, β= 1.46, p b 0.0001, n = 362) and D) males (
pression units.2.5. Cell culture models
Three CRC cell lines (CACO2, HT29 and HCT116) were provided by
Dr Jennette Sakoff (Department of Medical Oncology Calvary Mater
Newcastle Hospital). Cells were adapted into folate-free RPMI (with
10% FCS) over 3 weeks. After 3 weeks cells were cultured (24 well
plates; 0.2 × 106 cells/ml) and stimulated with no added folate
(deﬁcient), 0.001 mg/ml folate (control, equivalent to folate content in
standard RPMI-1640; pterylmonoglutamic acid, Schircks Laboratories,
Jona, Switzerland), or 0.01 mg/ml folate (excess). After 72 h media
were removed for isolation of secreted miRNA and miR-21 assayed,
as above. WST-1 assay (Biovision Research Products, CA, USA) was
conducted as per manufacturer's instructions to assess cellular prolifer-
ation over the culture period. Results were expressed as miR-21 (REU)
and normalized to relative cellular proliferation.2.6. Statistics
Statistical analyses were performed using JMP (Version 11, SAS
Institute Inc., Cary, NC, USA). T-tests, ANOVA (Tukey–Kramer post hoc
test) and Walds χ2 were used to compare categories. Multivariable
correlations were analysed by either least squares or nominal logistic
regression analysis as appropriate. Outcomes were considered to be
statistically signiﬁcant at p ≤ 0.05. Descriptive statistics have been calcu-
lated as appropriate. Where more than 5 variables were to be consid-
ered in a single analysis, mixed direction stepwise regression was
performed using signiﬁcance levels of p ≤ 0.250 or p N 0.250 to enter
(forward step) or remove (backward step) variables from the model,
respectively. Mallow's Cp criterion was used for selecting the model
where Cp ﬁrst approaches p variables.β=3.13, p=0.0001, n=144) andB)males (r2=0.05,β=1.25, p=0.03, n=109) from
r2 = 0.160, β= 1.16, p b 0.0001, n = 287) from the secondary cohort. REU= relative ex-
Fig. 3. SerummiR-21 expression by: MTHFR-C677T genotype in A) females and B)males;
DHFR-19 del genotype in C) females and D) males; and, MSR-A66G genotype in
E) females and F) males of the primary cohort. REU = relative expression units; “+” =
no deletion, “−”= 19 bp deletion.
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3.1. Plasma miR-21 expression is elevated in female patients with
adenomatous polyps
In the primary cohort cases had higher levels of plasmamiR-21 than
controls in females (1.85± 0.27 vs 0.07± 0.27 REU, p = 0.02; Fig. 1A),
but not in males (−0.08± 0.40 vs 0.50± 0.33, p = 0.26; Fig. 1B). Ad-
justment for age did not signiﬁcantly alter the results (females p=0.01,
males p=0.36). In the primary cohort females did not have signiﬁcant-
ly different levels of serummiR-21, compared to males (0.39± 0.26 vs
0.34 ± 0.26 REU, p = 0.89). However, in the secondary cohort
females had lower serum miR-21 levels (−0.42 ± 0.08 vs −0.09 ±
0.09, p = 0.0065). Additional descriptive statistics for the primary and
secondary cohorts are shown in Tables 1 and 2, respectively.
Serum miR-21 expression did not vary signiﬁcantly with age in
females (primary cohort r2 = 0.007, β = 0.03, p = 0.25; secondary
cohort r2 = 0.0003, β = 0.004 p = 0.73; supplementary Fig. 1) or
males (primary cohort r2 = 0.02, β=0.01, p = 0.59; secondary cohort
r2 = 0.008 β=−0.02 p= 0.14; supplementary Fig. 1). Smoking status
(never smoker, ex-smoker, current smoker) did not signiﬁcantly inﬂu-
ence serum miR-21 expression in females (primary cohort r2 = 0.004,
F = 0.30, p = 0.74; secondary cohort: r2 = 0.0003, F = 0.06, p =
0.94; supplementary Fig. 2) or males (primary cohort r2 = 0.01, F =
0.57, p=0.56; secondary cohort r2=0.006, F=0.85, p=0.43; supple-
mentary Fig. 2).
3.2. Relationship between nutrients and biochemicals of one-carbon
metabolism and serum miR-21 expression
Levels of folate (erythrocyte bound) and serum B12, homocysteine
and cysteine were available in the primary cohort. In this cohort, cases
had signiﬁcantly higher folate than controls in females (1.29 ± 0.12 vs
0.93 ± 0.04 nmol L−1, p = 0.0086; Table 1), but not males (0.89 ±
0.07 vs 1.1 ± 0.05 nmol L−1, p = 0.06; Table 1). Serum B12, homocys-
teine and cysteine levels did not vary signiﬁcantly between cases and
controls in either sex (Table 1).
In the primary cohort miR-21 expression varied signiﬁcantly with
folate levels in both females (r2 = 0.248, β= 3.13 p b 0.0001; Fig. 2A)
andmales (r2=0.05,β=1.25, p=0.03; Fig. 2B). SerumB12, homocys-
teine and cysteine did not signiﬁcantly inﬂuence miR-21 expression
levels (supplementary Table 1). Serum miR-21 expression also varied
signiﬁcantly with folate levels in the secondary cohort (females: r2 =
0.140, β = 1.46 p b 0.0001, males: r2 = 0.160, β = 1.16 p b 0.0001;
Fig. 2C–D) supplementary Table 2. Serum B12 and homocysteine levels
did not signiﬁcantly inﬂuence serum miR-21 expression in the second-
ary cohort (supplementary Table 2). In the secondary cohort data on
blood cysteine levels were not available.
3.3. Relationship between polymorphisms in one-carbon metabolism
enzymes and serum miR-21 expression
Multiple enzymes are involved in the production of methyl groups
from methyl-donor nutrients. Polymorphisms in the genes coding for
these enzymes can therefore inﬂuence methyl group production. In
the primary cohort, information was available for 8 common polymor-
phisms of 6 genes involved in this pathway (DHFR-19 del, TS-2R3R,
SHMT-C1420T, MTHFR-C677T, MTHFR-A1298C, MTHFR-G1793A, MS-
A2756G, MSR A66G). Genotypic frequencies in the primary cohort are
shown in supplementary Table 3.
In the primary cohort stepwise regression analysis identiﬁed
MTHFR-C677T and DHFR-19 del for inclusion in the models for both
miR-21 expression in both females and males, and further identiﬁed
MTHFR-G1793A in females and MSR-A66G and SHMT-C1420T in
males. After combined modelling, DHFR-19 del (p = 0.0036) and
MTHFR-C677T (p = 0.0083) were signiﬁcantly related to serum miR-21 expression in females (model r2 = 0.16, p = 0.0006), and MTHFR-
C677T (p = 0.0009) and MSR-A66G (p = 0.0443) were signiﬁcantly
related to serum miR-21 expression in males (model r2 = 0.21, p =
0.0019). In both females and males presence of the T allele of the
MTHFR-C677T polymorphism corresponded to higher serum miR-21
(Fig. 3A–B). In females only, the presence of the DHFR-19 bp deletion
corresponded to lower serum miR-21 (Fig. 3C–D). In males only, the
presence of the G allele of the MSR-A66G variant correlated with
decreased miR-21 expression in serum (Fig. 3E–F).
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for all subjects, however, DHFR-19 del and MSR-A66G genotype data
were only available for 200 participants. Genotypic frequencies are
shown in supplementary Table 4. After combined modelling, DHFR-19
del (p = 0.0154) and MTHFR-C677T (p = 0.0011) were signiﬁcantly
related to serum miR-21 expression in females (model r2 = 0.137,
p = 0.0017), validating the ﬁndings from the primary cohort. In males
MTHFR-C677T (p = 0.0036) was signiﬁcantly related to serum miR-
21 expression, however the association between MSR-A66G and miR-
21 expression in serum was not validated in the secondary cohort
(p = 0.9851) (model r2 = 0.174, p = 0.0218).
3.4. Combined models
Combining all parameters previously identiﬁed as signiﬁcant in
females in the primary cohort folate, MTHFR-C677T, and DHFR-19 del
produced a regression model with an adjusted r2 of 0.27 (p b 0.0001),
and an adjusted r2 of 0.206 (p b 0.0001) in the secondary cohort.
Similarly, combining all parameters identiﬁed as signiﬁcant in males
in the primary cohort (folate, MTHFR-C677T, MSR-A66G) resulted in a
model with an adjusted r2 of 0.15 (p b 0.0006), and an adjusted r2 of
0.235(p = 0.0002) in the secondary cohort. When adjusted for these
other variables, AP was not a signiﬁcant predictor for serum miR-21
expression (females p = 0.22, males p = 0.99).
Combined regression models including all available genotypic,
nutrient and biochemical variables against miR-21 expression were
also conducted in the primary cohort. This resulted in an adjusted r2
of 0.32 (p b 0.0001) in females and 0.20 (p= 0.03) inmales. In females,
folate,MTHFR-C677T (p b 0.0001), DHFR-19 del (p=0.04) andMTHFR-
G1793A (p = 0.02) were identiﬁed as signiﬁcant parameters in this
model. In males MTHFR-C677T (p = 0.05), DHFR-19 del (p = 0.04)
and MSR-A66G (p = 0.02) were identiﬁed as signiﬁcant parameters.
Exclusion of variables using a step-wise approach did not improve the
predictive value of the r2. When adjusted for all variables, AP was not
a signiﬁcant predictor for serum miR-21 expression (females p =
0.54, males p = 0.72).
3.5. MiR-21 expression in media is increased after folic acid stimulation in
colon cancer cell lines
After 72 h of culture, miR-21 levels in media were signiﬁcantly
higher in those stimulated with excess folic acid, relative to control
levels in all cell lines (CACO2: 0.06 vs −0.74 REU, p = 0.02; HT29:
0.82 vs −0.12, p = 0.01; HCT116: 0.43 vs −0.82 p = 0.01; Fig. 4).Fig. 4. Serum miR-21 expression in colorectal cancer cell line cultures with deﬁcient, control a
expression units, normalized to percentage proliferation. Data shown is mean ± standard erromiR-21 expression in folate deﬁcient cellswas not signiﬁcantly different
to control levels in all cell lines.miR-21 expression inmedia, normalized
to cellular proliferation did not signiﬁcantly inﬂuence these relation-
ships (supplementary Fig. 3).4. Discussion
A number of studies to date have suggested thatmiR-21maymake a
practical and sensitive biomarker for diagnosis and prognosis of AP and
CRC [5,10–12]. However, study sizes and diversity of populations have
been limited. The largest study to date is that of Toiyama et al. [10],
which included 186 CRC patients, 43 advanced AP patients and 53
healthy controls, however, this was limited to a cohort completely of
Japanese origin. As frequencies of genetic polymorphisms and sociocul-
tural habits, including diet, can vary with ethnic diversity and location,
studies such as this in additional populations are required to elucidate
the relationships between genetics, environmental stimuli, disease
and biomarkers.
In our Australian cohort, we have demonstrated that while serum
miR-21 signiﬁcantly increased in females with AP, the same trend was
not seen in males. However, blood folate levels and folate related
genetics were also a signiﬁcant predictor of serum miR-21 expression.
This may result from confounding or co-correlation, as AP and CRC,
and associated surgeries and treatments, may inﬂuence diet, uptake or
processing of nutrients, and CRC has known dietary risk factors [44,
45]. Importantly, when these additional factorswere taken into account,
serum miR-21 expression was no longer signiﬁcantly associated with
AP status. The observations of the correlation between folate status
and serum miR-21 in human cohorts is supported by the increased
release of miR-21 into media following excess folate stimulation in
colon cancer cell culture models. Importantly, in cell culture, excess
folate stimulation resulted in increased release of miR-21, even when
results were corrected for proliferation, suggesting that the increased
secretion is due to increased release, and not just an increased number
of cells available for secretion.
The relationship between folate and AP and CRC risk may be a
complicated one, with dose dependent biochemical and temporal
considerations [30,46]. In Australia a programme of mandatory folic
acid fortiﬁcation in bread ﬂour has existed since 2009 [47]. Themajority
of the samples of the primary cohort were collected during the volun-
tary phase-in period from2007–2009, and the samples of the secondary
cohort were collected entirely post-fortiﬁcation. Therefore, potential
exists for modulation of these relationships in populations withnd excess levels of folic acid in A) CACO2, B) HT29, and C) HCT116 cells. REU = relative
r of mean. 3 replicates per group.
50 E.L. Beckett et al. / BBA Clinical 4 (2015) 45–51different exposures from diet, including in those not exposed to folic
acid fortiﬁcation programmes.
All the polymorphisms that were found to be associated with serum
miR-21 expression in this study are non-synonymous polymorphisms
and can inﬂuence the regulation of one-carbon metabolism [31].
While MTHFR-C677T, DHFR-19 del and MSR-A66G genotypes did not
differ signiﬁcantly between cases and controls in the primary cohort,
others have shown conﬂicting inﬂuences of the presence of the TT
genotype on CRC risk [48–55], which may be explained by complex
gene–nutrient interactions [32,49,56,57]. However, it is not yet clear
what role differences in serum miR-21 expression play in this
relationship.
The presented data demonstrates that serum miR-21 expression
correlates with folate status and related genetic status. However, strati-
ﬁcation by gender revealed that this relationship only existed in
females. Although the sample size for this study was similar to previous
studies, additional studies are needed to determine if this is due to a
gender speciﬁc difference in diet or other gender differences.
Dietary modulation may have consequences for miR-21 and other
miRNAs in their proposed uses as CRC biomarkers. While it may indeed
be worthwhile pursuing miR-21 as biomarker for use in AP and CRC
diagnosis and prognosis, this data suggests that dietary variables may
inﬂuence the expression of miR-21, and that nutritional status may
need to be considered as part of its assessment of a biomarker.
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